Express Scripts ClearNetworkSM offers employers and health plans a new option for simple, "cost-plus" pharmacy pricing for brand, generic, and specialty medications. "We are constantly innovating to ...

LAKELAND, Fla. (Ivanhoe Newswire) - Niemann-Pick Type C, or NPC is a relentlessly progressive and fatal genetic disorder that impacts both the body and the brain. In the U.S., only about 900 people ...

A Zevra Therapeutics drug is now the first FDA-approved therapy for an ultra-rare, inherited metabolic disorder whose effects on the central nervous system can become fatal by the time a patient is a ...

INDIANAPOLIS (WISH) — Niemann-Pick Type C, or NPC, is a relentlessly progressive and fatal genetic disorder that impacts both the body and the brain. In the U.S., only about 900 people are living with ...

As the Sept. 21 PDUFA date looms for arimoclomol from Zevra Therapeutics Inc. in Niemann-Pick type C (NPC), the U.S. FDA’s newly formed Genetic Metabolic Diseases Advisory Committee (GeMDAC) decided ...

CENTOGENE and Insilico Medicine will work together to identify, rank, and annotate proteins to identify novel therapeutic targets for NPC using AI NPC is a rare genetic disease occurring in ...

Miplyffa was the first product application to be discussed at the inaugural Genetic Metabolic Diseases Advisory Committee meeting. The safety and effectiveness of Miplyffa were evaluated in a ...

After gaining FDA approval for Miplyffa ® (arimoclomol) as the first-ever therapy indicated to treat Niemann-Pick disease type C (NPC), Zevra Therapeutics has cashed in on the regulatory win by ...

Bloomsbury Genetic Therapies Ltd. has announced U.S. and E.U. orphan drug designations for BGT-NPC, an investigational gene therapy for the treatment of Niemann-Pick disease type C (NPC). BGT-NPC is ...

Coherus and Chinese partner Junshi Biosciences announced U.S. FDA approval of Loqtorzi in all lines of treatment for nasopharyngeal carcinoma (NPC). Coherus management has insisted they will "not ...